Icatibant Acetate shortage — IT supply status & alternatives

Icatibant Acetate

—

In supply · Australia

Icatibant

In supply · 🇦🇺 Australia · short in🇮🇹 IT🇺🇸 US

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$420.88DPMQ A$470.29details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Icatibant Acetate

Brand names	Icatibant

Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$420.88

AEMP

Dispensed (DPMQ)

A$470.29

incl. fees

Pack

icatibant 30 mg/3 mL injection, 3 mL syringe

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

16 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Cipla LTDChengdu Shengnuo Biopharm CO LTDBachem AGBcn Peptides SAAmbio INCTapi Nl BV+10 more

Manufacturing countries: India, China, Switzerland, Spain, United States, Italy · Source: FDA List of Drug Master Files

Verified timeline regulator events

🇮🇹 10 Aug 2026

critical reported

🇮🇹 11 May 2026

critical reported

🇺🇸 7 May 2026

medium reported

🇮🇹 24 Mar 2026

critical reported

🇮🇹 12 Dec 2023

critical reported

🇮🇹 31 May 2023

Shortage resolved

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.